Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global I.V. Iron Drugs Market by Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others) for the regions (North America, Europe, AsiaPacific and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Brazil, South Africa).

Over the recent years, the global Intravenous (IV) Iron Drug industry has been driven by the rising high prevalence of Iron Deficiency with unfulfilled need, rising awareness, growing prevalence of diseases leading to severe Iron Deficiency and increasing healthcare expenditure in emerging economies. Globally, the growth in IV Iron drug market is driven by growing middle class population group demanding better drugs to improve lifestyle.

According to our report report, Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022), global market is projected to display a robust growth represented by a CAGR of 11.19% by value during 2017 2022, chiefly driven by increase in healthcare spending and rising prevalence of diseases with Iron deficiency, emerging second & third generation IV Iron drugs and growing middle class income group coupled with rising health consciousness.

Among the therapeutic application type, nephrology accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with Iron Deficiency and unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.

The report titled, Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022) has covered and analysed the potential of IV Iron Drug Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global IV Iron Drug market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

Global IV Iron Drug Market, By Value
By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value
Regional Markets North America, Europe, APAC, and ROW (Actual Period: 2012-2016, Forecast Period: 2017-2022)
By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value
Country Analysis - United States, Canada, United Kingdom, Germany, France, China, India, Japan, Brazil and South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)
By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value
Other Report Highlights
Market Dynamics Trends, Drivers, Challenges, Policy and Regulation
Company Analysis Galenica; AMAG Pharmaceuticals, Inc; PHARMACOSMOS A/S; Allergan PLC; DAIICHI SANKYO COMPANY, LIMITED; NIPPON SHINYAKU CO., LTD and Sanofi
Customization of the Report

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.